Last10K.com

Pulse Biosciences, Inc. (PLSE) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Pulse Biosciences, Inc.

CIK: 1625101 Ticker: PLSE

Exhibit 99.1



PULSE BIOSCIENCES QUARTERLY INVESTOR CONFERENCE CALL



Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT



HAYWARD, Calif.—(BUSINESS WIRE) – March 16, 2018 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform today reports recent corporate developments and financial results for the fiscal quarter and year ended December 31, 2017.



Recent Developments



·

Successfully completed patient treatments and primary follow-up in the Company’s first clinical study evaluating Nano-Pulse Stimulation for the treatment of a benign skin condition, Seborrheic Keratosis(SK).  The study resulted in the successful delivery of 472 NPS applications involving 58 patients and 174 SK lesions, with ZERO ADVERSE EVENTS reported. The data adds to the mounting evidence regarding the safety and ease with which patients can be treated with NPS for skin-based lesions. The study data is scheduled for presentation in a scientific symposium at the 38th American Society for Laser Medicine and Surgery (ASLMS) Conference on Energy-Based Medicine & Science being held April 13-15 in Dallas, Texas. The data will be made available in a press release issued in conjunction with the scientific presentation.

·

An additional study “A dose-response study of a novel non-thermal method of selectively modifying cellular structure in skin with low energy nanosecond electrical stimulation” was also accepted for presentation at the ASLMS Conference and awarded “BEST OF SESSION” honors by ASLMS.

·

Completed enrollment and follow-up on five animals in the company’s investigational feasibility study evaluating NPS for the treatment of late stage oral melanoma in canines.

·

Published “Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response” in the peer-reviewed journal, PLOS One.

2017 was a transformational year for Pulse Biosciences as we completed patient treatments and follow-up in our first skin lesion study, advanced our oncology program with preclinical publications and an investigational feasibility study in veterinary medicine, welcomed four new board members, and secured the financing necessary to advance our proprietary technologies,” said Darrin Uecker, President and Chief Executive Officer. “We are well positioned to make significant advancements in 2018 and are most pleased with our successful SK study and look forward to sharing the results of the study in April.” 


The following information was filed by Pulse Biosciences, Inc. (PLSE) on Friday, March 16, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Pulse Biosciences, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pulse Biosciences, Inc..

Continue

Assess how Pulse Biosciences, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pulse Biosciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (parenthetical)
Accrued Expenses
Accrued Expenses (schedule Of Accrued Expenses) (details)
Accrued Expenses (tables)
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (schedule Of Minimum Future Lease Payments Remaining) (details)
Commitments And Contingencies (tables)
Description Of The Business
Employee Benefit Plans
Employee Benefit Plans (narrative) (details)
Goodwill
Goodwill (narrative) (details)
Income Taxes
Income Taxes (components Of Deferred Tax Assets) (details)
Income Taxes (narrative) (details)
Income Taxes (reconcilement Of Tax Rates) (details)
Income Taxes (reconciliation Of Unrecognized Tax Benefit Accounts) (details)
Income Taxes (tables)
Intangible Assets (schedule Of Amortization Of Intangible Assets) (details)
Intangible Assets, Net
Intangible Assets, Net (schedule Of Intangible Assets, Net) (details)
Intangible Assets, Net (tables)
Investments And Fair Value Of Financial Instruments
Investments And Fair Value Of Financial Instruments (fair Value Of Financial Assets Measured On A Recurring Basis) (details)
Investments And Fair Value Of Financial Instruments (narrative) (details)
Investments And Fair Value Of Financial Instruments (schedule Of Available-for-sale Securities) (details)
Investments And Fair Value Of Financial Instruments (schedule Of Contractual Maturities) (details)
Investments And Fair Value Of Financial Instruments (tables)
Property And Equipment, Net
Property And Equipment, Net (narrative) (details)
Property And Equipment, Net (schedule Of Property And Equipment, Net) (details)
Property And Equipment, Net (tables)
Related Party Transactions
Related Party Transactions (narrative) (details)
Research Grants And Agreements
Research Grants And Agreements (narrative) (details)
Selected Quarterly Financial Data
Selected Quarterly Financial Data (narrative) (details)
Selected Quarterly Financial Data (schedule Of Selected Quarterly Financial Data) (details)
Selected Quarterly Financial Data (tables)
Stockholders' Equity And Stock-based Compensation
Stockholders' Equity And Stock-based Compensation (narrative) (details)
Stockholders' Equity And Stock-based Compensation (schedule Of Fair Value Of Employee Stock Options) (details)
Stockholders' Equity And Stock-based Compensation (summary Of Exercise Price Of Stock Options Outstanding And Exercisable) (details)
Stockholders' Equity And Stock-based Compensation (summary Of Stock Option Activity) (details)
Stockholders' Equity And Stock-based Compensation (summary Of Stock Warrant Activity) (details)
Stockholders' Equity And Stock-based Compensation (summary Of Stock-based Compensation Expense) (details)
Stockholders' Equity And Stock-based Compensation (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (anti-dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (details)
Summary Of Significant Accounting Policies (narrative) (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Ticker: PLSE
CIK: 1625101
Form Type: 10-K Annual Report
Accession Number: 0001625101-18-000012
Submitted to the SEC: Fri Mar 16 2018 3:51:55 PM EST
Accepted by the SEC: Fri Mar 16 2018
Period: Sunday, December 31, 2017
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/plse/0001625101-18-000012.htm